Participants in an international conference on prophylactic therapy for severe haemophilia developed a consensus summary of the findings and conclusions of the conference. In the consensus, participants agreed upon revised definitions for primary and secondary prophylaxis and also made recommendations concerning the need for an international system of pharmacovigilance. Considerations on starting prophylaxis, monitoring outcomes, and individualizing treatment regimens were discussed. Several research questions were identified as needing further investigation, including when to start and when to stop prophylaxis, optimal dosing and dose interval, and methods for assessment of long-term treatment effects. Such studies should include carefully defined cohorts, validated orthopaedic and quality-of-life assessment instruments, and cost-benefit analyses

Consensus perspectives on prophylactic therapy for haemophilia : summary statement / E. Berntorp, J. Astermark, S. Björkman, V. S. Blanchette, K. Fischer, P. L. F. Giangrande, A. Gringeri, R. C. Ljung, M. J. Manco-Johnson, M. Morfini, R. F. Kilcoyne, P. Petrini, E. C. Rodriguez-Merchan, W. Schramm, A. Shapiro, H. M. van Den Berg, C. Hart. - In: HAEMOPHILIA. - ISSN 1351-8216. - 9:Suppl. 1(2003 May), pp. 1-4.

Consensus perspectives on prophylactic therapy for haemophilia : summary statement

A. Gringeri;
2003

Abstract

Participants in an international conference on prophylactic therapy for severe haemophilia developed a consensus summary of the findings and conclusions of the conference. In the consensus, participants agreed upon revised definitions for primary and secondary prophylaxis and also made recommendations concerning the need for an international system of pharmacovigilance. Considerations on starting prophylaxis, monitoring outcomes, and individualizing treatment regimens were discussed. Several research questions were identified as needing further investigation, including when to start and when to stop prophylaxis, optimal dosing and dose interval, and methods for assessment of long-term treatment effects. Such studies should include carefully defined cohorts, validated orthopaedic and quality-of-life assessment instruments, and cost-benefit analyses
Diagnosis; Guidelines; Haemophilia; Treatment
Settore MED/09 - Medicina Interna
mag-2003
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/156926
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 189
  • ???jsp.display-item.citation.isi??? 187
social impact